PML-RARA fusion
|
Acute Promyelocytic Leukemia
|
PML-RARA fusion
|
Acute Promyelocytic Leukemia
|
arsenic trioxide Sensitive: A1 - Approval
|
arsenic trioxide Sensitive: A1 - Approval
|
PML-RARA fusion
|
AML
|
PML-RARA fusion
|
AML
|
venetoclax Sensitive: C3 – Early Trials
|
venetoclax Sensitive: C3 – Early Trials
|
PML-RARA fusion
|
Acute Promyelocytic Leukemia
|
PML-RARA fusion
|
Acute Promyelocytic Leukemia
|
tretinoin + arsenic trioxide Sensitive: C3 – Early Trials
|
tretinoin + arsenic trioxide Sensitive: C3 – Early Trials
|
PML-RARA fusion
|
Acute Promyelocytic Leukemia
|
PML-RARA fusion
|
Acute Promyelocytic Leukemia
|
cytarabine + idarubicin hydrochloride + tretinoin Sensitive: C4 – Case Studies
|
cytarabine + idarubicin hydrochloride + tretinoin Sensitive: C4 – Case Studies
|
PML-RARA fusion
|
AML
|
PML-RARA fusion
|
AML
|
tretinoin Sensitive: C4 – Case Studies
|
tretinoin Sensitive: C4 – Case Studies
|